The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Cancer Cell Resistance Against the Clinically Investigated Thiosemicarbazone COTI-2 Is Based on Formation of Intracellular Copper Complex Glutathione Adducts and ABCC1-Mediated Efflux
Abstract
COTI-2 is a novel anticancer thiosemicarbazone in phase I clinical trial. However, the effects of metal complexation (a main characteristic of thiosemicarbazones) and acquired resistance mechanisms are widely unknown. Therefore, in this study, the copper and iron complexes of COTI-2 were synthesized and evaluated for their anticancer activity and impact on drug resistance in comparison to metal-free thiosemicarbazones. Investigations using Triapine-resistant SW480/Tria and newly established COTI-2-resistant SW480/Coti cells revealed distinct structure–activity relationships. SW480/Coti cells were found to overexpress ABCC1, and COTI-2 being a substrate for this efflux pump. This was unexpected, as ABCC1 has strong selectivity for glutathione adducts. The recognition by ABCC1 could be explained by the reduction kinetics of a ternary Cu-COTI-2 complex with glutathione. Thus, only thiosemicarbazones forming stable, nonreducible copper(II)-glutathione adducts are recognized and, in turn, effluxed by ABCC1. This reveals a crucial connection between copper complex chemistry, glutathione interaction, and the resistance profile of clinically relevant thiosemicarbazones.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“COTI-2 has been shown to suppress tumor growth by inducing apoptosis and cell cycle arrest in both p53-dependent and p53-independent manners.356,358”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [358]
In the citing paper
“COTI-2 inhibits tumor growth in a p53-dependent and p53-independent manner, ultimately leading to cell cycle arrest and apoptosis.448–450”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [450]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Revisiting the role of ABC transporters in multidrug-resistant cancer
Robey, R. W., Pluchino, K. M., Hall, M. D., Fojo, A. T., Bates, S. E., & Gottesman, M. M. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0005-8 · Cited by 1,866
Research works printed but not linked: 42
- Lobana, 2009, Bonding and structure trends of thiosemicarbazone derivatives of metals-An overview, Coord. Chem. Rev., 253, 977, 10.1016/j.ccr.2008.07.004 · doi:10.1016/j.ccr.2008.07.004
- Beraldo, 2004, The wide pharmacological versatility of semicarbazones, thiosemicarba-zones and their metal complexes, Mini-Rev. Med. Chem., 4, 31, 10.2174/1389557043487484 · DOI · Paper page
- Yu, 2009, Thiosemicarbazones from the old to new: Iron chelators that are more than just ribonucleotide reductase inhibitors, J. Med. Chem., 52, 5271, 10.1021/jm900552r · DOI · Paper page
- Heffeter, 2019, Anticancer thiosemicarbazones: chemical properties, interaction with iron metabolism, and resistance development, Antioxid. Redox Signaling, 30, 1062, 10.1089/ars.2017.7487 · DOI · Paper page
- Lovejoy, 2011, Antitumor Activity of Metal-Chelating Compound Dp44mT Is Mediated by Formation of a Redox-Active Copper Complex That Accumulates in Lysosomes, Cancer Res., 71, 5871, 10.1158/0008-5472.CAN-11-1218 · DOI · Paper page
- Hager, 2020, High copper complex stability and slow reduction kinetics as key parameters for improved activity, paraptosis induction and impact on drug-resistant cells of anticancer thiosemicarbazones, Antioxid. Redox Signaling, 33, 395, 10.1089/ars.2019.7854 · doi:10.1089/ars.2019.7854
- Miah, 2010, Triapine in clinical practice, Eur. J. Clin. Med. Oncol., 2, 1
- Kowol, 2009, Impact of Metal Coordination on Cytotoxicity of 3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone (Triapine) and Novel Insights into Terminal Dimethylation, J. Med. Chem., 52, 5032, 10.1021/jm900528d · DOI · Paper page
- Kowol, 2016, Impact of Stepwise NH2-Methylation of Triapine on the Physicochemical Properties, Anticancer Activity, and Resistance Circumvention, J. Med. Chem., 59, 6739, 10.1021/acs.jmedchem.6b00342 · DOI
- Hager, 2018, The thiosemicarbazone Me2NNMe2 induces paraptosis by disrupting the ER thiol redox homeostasis based on protein disulfide isomerase inhibition, Cell Death Dis., 9, 1052, 10.1038/s41419-018-1102-z · doi:10.1038/s41419-018-1102-z
- Guo, 2016, The novel thiosemicarbazone, di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), inhibits neuroblastoma growth in vitro and in vivo via multiple mechanisms, J. Hematol. Oncol., 9, 98, 10.1186/s13045-016-0330-x · DOI
- Seebacher, 2016, A mechanism for overcoming P-glycoprotein-mediated drug resistance: novel combination therapy that releases stored doxorubicin from lysosomes via lysosomal permeabilization using Dp44mT or DpC, Cell Death Dis., 7, e2510, 10.1038/cddis.2016.381 · DOI
- Salim, 2016, COTI-2, a new anticancer drug currently under clinical investigation, targets mutant p53 and negatively modulates the PI3K/AKT/mTOR pathway, Eur. J. Cancer, 69, S19, 10.1016/S0959-8049(16)32638-7 · DOI
- Lindemann, 2019, COTI-2, a novel thiosemicarbazone derivative, exhibits antitumor activity in HNSCC through p53-dependent and -independent mechanisms, Clin. Cancer Res., 25, 5650, 10.1158/1078-0432.CCR-19-0096 · DOI · Paper page
- Salim, 2016, COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo, Oncotarget, 7, 41363, 10.18632/oncotarget.9133 · DOI · Paper page
- Miklos, 2015, Triapine-mediated ABCB1 induction via PKC induces widespread therapy unresponsiveness but is not underlying acquired triapine resistance, Cancer Lett., 361, 112, 10.1016/j.canlet.2015.02.049 · DOI
- Heffeter, 2012, Impact of terminal dimethylation on the resistance profile of α-N-heterocyclic thiosemicarbazones, Biochem. Pharmacol., 83, 1623, 10.1016/j.bcp.2012.03.004 · DOI
- Wiese, 2019, The A-B-C of small-molecule ABC transport protein modulators: From inhibition to activation─a case study of multidrug resistance-associated protein 1 (ABCC1), Med. Res. Rev., 39, 2031, 10.1002/med.21573 · DOI
- Cole, 2006, Transport of glutathione and glutathione conjugates by MRP1, Trends Pharmacol. Sci., 27, 438, 10.1016/j.tips.2006.06.008 · DOI · Paper page
- Lemke, 1977, Synthesis of 5,6-dihydro-8(7H)-quinolinone thiosemicarbazones as potential antitumor agents, J. Med. Chem., 20, 1351, 10.1021/jm00220a026 · doi:10.1021/jm00220a026
- Kowol, 2007, Effect of metal ion complexation and chalcogen donor identity on the antiproliferative activity of 2-acetylpyridine N,N-dimethyl(chalcogen)semicarbazones, J. Inorg. Biochem., 101, 1946, 10.1016/j.jinorgbio.2007.07.026 · doi:10.1016/j.jinorgbio.2007.07.026
- Pessôa, 2001, 2-Formylpyridinethiosemicarbazone and methyl derivatives: Spectroscopic studies, Polyhedron, 20, 3133, 10.1016/S0277-5387(01)00928-7 · doi:10.1016/s0277-5387(01)00928-7
- ChemAxon., 2012, Instant J Chem/MarvinSketch
- Richardson, 2006, Dipyridyl Thiosemicarbazone Chelators with Potent and Selective Antitumor Activity Form Iron Complexes with Redox Activity, J. Med. Chem., 49, 6510, 10.1021/jm0606342 · DOI · Paper page
- Kowol, 2007, Gallium(III) and Iron(III) Complexes of α-N-Heterocyclic Thiosemicarbazones: Synthesis, Characterization, Cytotoxicity, and Interaction with Ribonucleotide Reductase, J. Med. Chem., 50, 1254, 10.1021/jm0612618 · doi:10.1021/jm0612618
- Kowol, 2012, Mechanisms underlying reductant-induced reactive oxygen species formation by anticancer copper(II) compounds, J. Biol. Inorg. Chem., 17, 409, 10.1007/s00775-011-0864-x · DOI
- Korp, 1978, Crystal and molecular structure of (Z)-5,6-dihydro-8(7H)quinolinone thiosemicarbazone, J. Cryst. Mol. Struct., 8, 115, 10.1007/BF01370422 · doi:10.1007/bf01370422
- Joseph, 2006, Structural, antimicrobial and spectral studies of copper(II) complexes of 2-benzoylpyridine N(4)-phenyl thiosemicarbazone, Polyhedron, 25, 61, 10.1016/j.poly.2005.07.006 · DOI
- Beshir, 2008, Synthesis and structure-activity relationships of metal-ligand complexes that potently inhibit cell migration, Bioorg. Med. Chem. Lett., 18, 498, 10.1016/j.bmcl.2007.11.099 · doi:10.1016/j.bmcl.2007.11.099
- Saswati, 2015, Synthesis, X-ray structure and in vitro cytotoxicity studies of Cu(I/II) complexes of thiosemicarbazone: special emphasis on their interactions with DNA, Dalton Trans., 44, 6140, 10.1039/C4DT03764B · DOI
- Miklos, 2016, Loss of phosphodiesterase 4D mediates acquired triapine resistance via Epac-Rap1-Integrin signaling, Oncotarget, 7, 84556, 10.18632/oncotarget.11821 · DOI
- Maleki Vareki, 2018, Novel anti-cancer drug COTI-2 synergizes with therapeutic agents and does not induce resistance or exhibit cross-resistance in human cancer cell lines, PLoS One, 13, 1, 10.1371/journal.pone.0191766 · DOI
- Yuan, 2004, Novel di-2-pyridyl–derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment, Blood, 104, 1450, 10.1182/blood-2004-03-0868 · DOI · Paper page
- Trondl, 2014, Triapine and a More Potent Dimethyl Derivative Induce Endoplasmatic Reticulum Stress in Cancer Cells, Mol. Pharmaceutics, 85, 451, 10.1124/mol.113.090605 · DOI
- Cserepes, 2020, Unshielding Multidrug Resistant Cancer through Selective Iron Depletion of P-Glycoprotein–Expressing Cells, Cancer Res., 80, 663, 10.1158/0008-5472.CAN-19-1407 · DOI
- Jansson, 2010, Novel Thiosemicarbazones of the ApT and DpT Series and Their Copper Complexes: Identification of Pronounced Redox Activity and Characterization of Their Antitumor Activity, J. Med. Chem., 53, 5759, 10.1021/jm100561b · DOI · Paper page
- Park, 2016, Copper and conquer: copper complexes of di-2-pyridylketone thiosemicarbazones as novel anti-cancer therapeutics, Metallomics, 8, 874, 10.1039/C6MT00105J · DOI
- Ishiguro, 2014, Distinct mechanisms of cell-kill by triapine and its terminally dimethylated derivative Dp44mT due to a loss or gain of activity of their copper(II) complexes, Biochem. Pharmacol., 91, 312, 10.1016/j.bcp.2014.08.006 · DOI
- Drew, 1984, The effects of buthionine sulphoximine (BSO) on glutathione depletion and xenobiotic biotransformation, Biochem. Pharmacol., 33, 2989, 10.1016/0006-2952(84)90598-7 · DOI
- Santoro, 2020, The Glutathione/Metallothionein System Challenges the Design of Efficient O2-Activating Copper Complexes, Am. Ethnol., 132, 7904, 10.1002/ange.201916316 · DOI
- Santoro, 2019, Reactivity of Cu (ii)–, Zn (ii)–and Fe (ii)–thiosemicarbazone complexes with glutathione and metallothionein: from stability to dissociation to transmetallation, Metallomics, 11, 994, 10.1039/C9MT00061E · DOI
- Kalinowski, 2016, Redox cycling metals: Pedaling their roles in metabolism and their use in the development of novel therapeutics, Biochim. Biophys. Acta, Mol. Cell Res., 1863, 727, 10.1016/j.bbamcr.2016.01.026 · DOI
Cited by
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Cuproptosis: A novel therapeutic target for overcoming cancer drug resistance
Wang, Y., Chen, Y., Zhang, J., Yang, Y., Fleishman, J. S., Wang, Y., Wang, J., Chen, J., Li, Y., & Wang, H. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2023.101018 · Cited by 256
Antifungal activity of thiosemicarbazones, bis(thiosemicarbazones), and their metal complexes
Bajaj, K., Buchanan, R. M., & Grapperhaus, C. A. (2021) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2021.111620 · Cited by 122
p53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 30
Metadata
- Authors
- Bormio Nunes, J. H., Hager, S., Mathuber, M., Pósa, V., Roller, A., Enyedy, E. A., Stefanelli, A., Berger, W., Keppler, B. K., Heffeter, P., & Kowol, C. R.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-11-16
- Volume
- 63
- Issue
- 22
- Pages
- 13719-13732
- ISSN
- 0022-2623
- 1520-4804
- Cited by
- 65
- References
- 1
- Language
- en
- Funders
- Österreichischen Akademie der Wissenschaften (NA)
- Austrian Science Fund (P31923)
- OeAD-GmbH (NA)
- Nemzeti Kutatási Fejlesztési és Innovációs Hivatal (FK 124240, TUDFO/47138-1/2019-ITM)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cancer Cell Resistance Against the Clinically Investigated Thiosemicarbazone COTI-2 Is Based on Formation of Intracellular Copper Complex Glutathione Adducts and ABCC1-Mediated Efflux. https://app.cochat.ai/papers/10.1021/acs.jmedchem.0c01277
- The paper
- Bormio Nunes, J. H., Hager, S., Mathuber, M., Pósa, V., Roller, A., Enyedy, E. A., Stefanelli, A., Berger, W., Keppler, B. K., Heffeter, P., & Kowol, C. R. (2020). Cancer Cell Resistance Against the Clinically Investigated Thiosemicarbazone COTI-2 Is Based on Formation of Intracellular Copper Complex Glutathione Adducts and ABCC1-Mediated Efflux. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.0c01277
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.